Compare Charles River Laboratories Intl. Inc (CRL) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Schwab US Large Cap Growth ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while Schwab US Large Cap Growth ETF trades at $36.75 (market cap $65.01B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 4.6× Charles River Laboratories Intl. Inc's market cap, and Schwab US Large Cap Growth ETF is more actively traded (8,554,399 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| CRL | SCHG | |
|---|---|---|
Market Cap | $14.23B | $65.01B |
Volume | 1,176,885 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $310.77 | $36.93 |
52-Week Low | $149.93 | $28.10 |
Typical Hold Time | 33 Days | 50 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
SCHG trades at $36.72, down 0.41% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's role in growth portfolios and tax-efficient strategies, with Seeking Alpha noting its valuation discount compared to QQQM as of September 9, 2026.
SCHG offers exposure to large-cap growth stocks with competitive fees, though concentration in top holdings presents both opportunity and risk. The ETF's performance is closely tied to megacap technology names, making it sensitive to sector rotations. Long-term growth potential remains supported by historical outperformance, but investors should monitor holding concentration and market leadership shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
